Clinical trial

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host…

NCT00089037 · Fred Hutchinson Cancer Center, Other · Completed

Key facts

NCT number NCT00089037
Title Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Official title A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors
Lead sponsor Fred Hutchinson Cancer Center, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 1/Phase 2
Study type Interventional
Conditions Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Intervention type Drug
Interventions methotrexate, sirolimus, tacrolimus
Start date Jun 1, 2003
Primary completion Apr 1, 2005
Completion Apr 1, 2005
First posted Aug 5, 2004
Last update posted Jul 15, 2011
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies